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Background: The human paraoxonase (PON) gene family has three isoforms: PON1, PON2 and PON3. These genes
are implicated as potential risk factors of cerebrovascular disease and can prevent oxidative modification of
low-density lipoproteins and atherosclerosis. This study evaluated the association between the genetic variants of
all three PON genes and the risks of total stroke, ischemic stroke and hemorrhagic stroke in the Han Chinese
population.
Methods: A total of 1016 subjects were recruited, including 508 healthy controls and 498 patients (328 with
ischemic stroke and 170 with hemorrhagic stroke). A total of 11 single nucleotide polymorphisms (SNPs) covering
the PON genes were genotyped for statistical analysis. Two of the 11 SNPs (rs662 and rs854560) were
contextualized in a meta-analysis of ischemic stroke.
Results: The presence of rs705381 (−162) in the promoter region of PON1 was significantly associated with total
stroke (Padjusted = 0.0007, OR = 0.57 [95% CI = 0.41-0.79]) and ischemic stroke (Padjusted = 0.0017, OR = 0.54 [95% CI =
0.37-0.79]) when analyzed using a dominant model, but was not associated with hemorrhagic stroke. There was
also a nominal association between rs854571 (−824) and total stroke. Meta-analysis demonstrated a significant
nominal association between rs662 and ischemic stroke, but there was no evidence of an association between
rs662 and ischemic stroke risk in a single site association study.
Conclusions: These findings indicate that polymorphisms of PON1 gene may be a risk factor of stroke.
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Stroke is recognized as one of the leading causes of
death and severe neurological disability worldwide. Is-
chemic and hemorrhagic stroke are the two primary
subtypes [1]. Data from family-based studies [2], twin
studies [3,4], and animal experiments [5,6] indicate that
genetic factors play a major role in stroke. A small iso-
lated group of strokes have previously been ascribed to
single-gene disorders [7].* Correspondence: shiyongyong@gmail.com; ymsun@capitalbio.com
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reproduction in any medium, provided the orIntermediate phenotypes of stroke are seen clinically.
Atherosclerosis, as an intermediate phenotype of stroke,
has been extensively investigated as a major underlying
cause of cardio- and cerebrovascular disease [8-10].
There is also a strong inverse association between high-
density lipoprotein (HDL) levels and the development of
atherosclerosis, and similar results have been found be-
tween low-density lipoprotein (LDL) peroxidation and
the development of atherosclerosis [11,12].
The paraoxonase (PON) gene family comprises three
isoforms, PON1, PON2 and PON3, located in 7q21.3-22.1
[13]. The 60 to 80% structural similarity among these
three members accounts for their functional similarity
[13,14]. All three isoforms have been implicated as candi-
date genes for atherosclerosis and cardiovascular diseases
due to their ability to attenuate lipid peroxidation, and due
to their antioxidant and antiatherogenic effects [15-17].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Comparison of clinical variables between total





Ischemic stroke, n 328
Hemorrhagic stroke, n 170
Age, years 60.45 ± 14.27* 56.48 ± 4.55
Male, n (%) 142 (28) 140 (28)
TC, mmol/L 4.41 ± 1.31 4.36 ± 1.33
TG, mmol/L 1.54 ± 0.95 1.56 ± 1.26
HDL, mmol/L 1.10 ± 0.28* 1.28 ± 0.27
LDL, mmol/L 2.54 ± 0.89 2.52 ± 0.56
Hypertension, n (%) 413 (83)* 310 (62)
Diabetes, n (%) 130 (26) 122 (24)
Data are shown as mean ± standard deviation (SD) or as n (%). Abbreviations:
TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-
density lipoprotein.*Significant differences between cases and controls.
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of atherosclerosis [18], and thereby contribute to a predis-
position towards stroke, coronary artery disease (CAD)
and vascular disorders in diabetes [19-21]. Other studies
have demonstrated a positive association between single
nucleotide polymorphisms (SNPs) in PON genes and
stroke susceptibility [22-25], although conflicting results
have been seen in different ethnic groups [26-28]. How-
ever, there are limited number of prospective studies valid-
ating the association between PON genes and the risk of
stroke in the Han Chinese population [26,28-30].
A negative association has previously been demon-
strated between SNPs in the coding region of PON1 and
PON2, and the development of stroke. In this study we
wanted to evaluate the levels of ischemic and hemorrhagic
risk conferred by SNPs in the whole PON family in a large
Chinese population. With this aim in mind, we conducted
a case–control study in the Han Chinese population to
evaluate the possible association of PON family genes with
total stroke and its subtypes.
Methods
Subjects
The study sample included 508 healthy controls and 498
patients, including 328 with ischemic stroke and 170
with hemorrhagic stroke who presented consecutively to
the Department of Neurology, Beijing Tiantan Hospital,
between December 2010 and March 2011. The subjects
were unrelated to one another and were recruited from
the Han Chinese population.
Hemorrhagic stroke included hypertensive cerebral
hemorrhage and subarachnoid hemorrhage. Patients with
hemorrhage due to trauma, tumor, vascular malformation
and coagulopathy were excluded. Ischemic stroke was
defined as a sudden onset of focal or global neurologic def-
icit with signs and symptoms persisting for more than 24 h.
Patients with a history or occurrence of transient ischemic
attack, cerebral embolism, cerebral trauma, cerebrovascular
malformations, coagulation disorders, autoimmune dis-
eases, tumors, peripheral vascular disease, or chronic infec-
tion diseases were excluded from the study.
All diagnoses were confirmed by brain computed tom-
ography and/or magnetic resonance imaging. The brain
images were independently assessed by a technologist
and a physician.
Control subjects were recruited from the health exam-
ination department of the Beijing Tiantan Hospital.
These subjects had no clinical or radiological evidence
of stroke and other neurological diseases. They were also
free from autoimmune disease, liver disease, nephrosis,
and hematological disorders
Sex, age, total plasma cholesterol (TC), triglycerides
(TG), HDL, and LDL cholesterol were documented on
entry into the study. Potential vascular risk factors wereevaluated, including hypertension, diabetes mellitus, atrial
fibrillation, and ischemic heart disease. Hypertension was
defined according to WHO/ISH criteria [31] as systolic
blood pressure ≥140 mmHg and/or diastolic pressure
≥ 90 mmHg with concomitant use of antihypertensive
medications Diabetes mellitus was defined as fasting
plasma glucose ≥7.0 mmol/L or current treatment with
anti-diabetic drugs.
The experimental protocol was approved by the Ethics
Committee of the Beijing Tiantan Hospital. Written
informed consent was obtained from all participants
prior to entering the study.Genotyping
Eleven single nucleotide polymorphisms (SNPs) were gen-
otyped. These included: rs662 (Gln192Arg), rs13306698
(Arg160Gly), rs854560 (Leu55Met) in coding region of
PON1; rs705379 (−107/-108), rs705381 (−160/-162),
rs854571 (−824/-832), rs854572 (−907/-909) in the pro-
moter of PON1; rs12026 (Ala148Gly) and rs7493 (Ser311Cys)
of PON2, together with rs2074353 (located in intron) and
rs1053275 (Ala99Ala) for PON3.
The SNPs were genotyped using the Sequenom Mass
ARRAY platform (Sequenom, San Diego, CA) according to
the iPLEX Gold Application Guide available at (http://
www.sequenom.com/sites/genetic-analysis/applications/
snp-genotyping). The genotyping analysis was undertaken
according to the manufacturer’s protocol, using recom-
mended reagents in the iPLEX Gold SNP genotyping kit.
Briefly, specific assays were designed using the Mass
ARRAY Assay Design software package (v3.1). The process
involved a locus-specific PCR reaction based on a locus-
specific primer extension reaction. Residual nucleotides
were dephosphorylated with SAP enzymes before undertak-
ing the iPLEX GOLD primer extension reactions.
Figure 1 Linkage disequilibrium analysis of the ten SNPs investigated in healthy controls (a). Four blocks were identified using Haploview
software: Block1 (rs854560-rs13306698-rs662); Block2 (rs854572-rs854571-rs705381); Block3 (rs1053275-rs2074353); Block4 (rs12026-rs7493) (b).
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products were desalinated with Spectro CLEAN resin
(Sequenom). A 10 nL aliquot of the desalinated product
was spotted onto a 384-format Spectro CHIP with the
Mass ARRAY Nanodispenser. Mass determination was
carried out with the MALDI-TOF mass spectrometer and
Mass ARRAY Type 4.0 software was used for data
acquisition.
SNP genotypes were named using cluster analysis with
a default parameter setting. Genotypes were further
reviewed manually to correct classification errors caused
by clustering artifacts.Statistical analysis
Statistical analysis was undertaken using PLINK software
(http://pngu.mgh.harvard.edu/~purcell/plink/) [32]. Hardy-
Weinberg equilibrium tests (HWE) were performed for
each SNP, and association tests were undertaken using
additive, dominant, or recessive genetic models.
Logistic regression was used for risk stratification with
or without covariate adjustments determined by signifi-
cant differences between total stroke patients and con-
trols (i.e. age, HDL, and hypertension). The model with
the highest likelihood was considered to provide the
best-fit genetic model for each SNP. Haplotype-based
Table 2 Association between SNPs and total stroke using the additive, dominant, genotype, and the recessive models
SNP Model Allele or
geno
F_Stroke F_Control T-Statistic Logistic Regression
OR (95% CI) Punadjusted OR (95% CI) Padjusted
rs854571 Additive C > T 298/992 344/982 0.79(0.65-0.96) 1.71E-02 0.80(0.65-0.98) 3.30E-02
Dominant CC + CT/TT 253/496 289/491 0.73(0.57-0.94) 1.33E-02 0.75(0.57-0.99) 3.96E-02
Recessive CC/CT + TT 45/496 55/491 0.79(0.52-1.20) 2.69E-01 0.75(0.48-1.17) 2.06E-01
rs13306698 Additive A > G 98/1016 98/988 0.97(0.71-1.31) 8.31E-01 1.00(0.71-1.40) 9.99E-01
Dominant AA + AG/GG 97/508 96/494 0.98(0.71-1.34) 8.92E-01 1.02(0.72-1.44) 9.20E-01
Recessive AA/AG + GG 1/508 2/494 0.49(0.04-5.37) 5.55E-01 0.39(0.03-5.06) 4.74E-01
rs854572 Additive C > G 443/1004 413/964 1.05(0.88-1.26) 5.69E-01 1.09(0.89-1.32) 4.08E-01
Dominant CC + CG/GG 343/502 324/482 1.05(0.81-1.38) 7.10E-01 1.11(0.82-1.48) 5.04E-01
Recessive CC/CG + GG 100/502 89/482 1.10(0.80-1.51) 5.62E-01 1.13(0.80-1.61) 4.93E-01
rs7493 Additive C > G 192/1016 176/974 1.06(0.84-1.33) 6.32E-01 1.00(0.78-1.29) 9.89E-01
Dominant CC + CG/GG 173/508 163/487 1.03(0.79-1.34) 8.45E-01 1.00(0.75-1.34) 9.85E-01
Recessive CC/CG + GG 19/508 13/487 1.42(0.69-2.90) 3.41E-01 1.00(0.46-2.18) 9.93E-01
rs662 Additive G > A 389/1014 356/978 1.08(0.91-1.29) 3.86E-01 1.05(0.87-1.28) 5.93E-01
Dominant GG + GA/AA 303/507 282/489 1.09(0.85-1.40) 5.02E-01 1.05(0.80-1.39) 7.31E-01
Recessive GG/GA + AA 86/507 74/489 1.15(0.82-1.61) 4.32E-01 1.12(0.77-1.62) 5.65E-01
rs12026 Additive C > G 192/1010 174/978 1.09(0.86-1.37) 4.80E-01 1.05(0.81-1.35) 7.17E-01
Dominant CC + CG/GG 173/505 162/489 1.05(0.81-1.37) 7.07E-01 1.05(0.78-1.40) 7.56E-01
Recessive CC/CG + GG 19/505 12/489 1.55(0.75-3.24) 2.39E-01 1.13(0.51-2.50) 7.72E-01
rs1053275 Additive A > G 203/1000 186/994 1.10(0.89-1.37) 3.82E-01 1.10(0.86-1.39) 4.53E-01
Dominant AA + AG/GG 179/500 165/497 1.12(0.86-1.46) 3.88E-01 1.13(0.85-1.51) 3.90E-01
Recessive AA/AG + GG 24/500 21/497 1.14(0.63-2.08) 6.62E-01 1.04(0.54-1.99) 9.17E-01
rs705381 Additive G > A 106/988 151/990 0.67(0.51-0.87) 3.13E-03* 0.67(0.50-0.89) 5.80E-03*
Dominant GG + GA/AA 95/494 144/495 0.58(0.43-0.78) 3.20E-04* 0.57(0.41-0.79) 7.10E-04*
Recessive GG/GA + AA 11/494 7/495 1.59(0.61-4.13) 3.43E-01 1.64(0.58-4.61) 3.52E-01
rs2074353 Additive A > G 253/996 230/982 1.11(0.91-1.36) 3.16E-01 1.12(0.90-1.40) 3.09E-01
Dominant AA + AG/GG 219/498 197/491 1.17(0.91-1.51) 2.20E-01 1.23(0.93-1.62) 1.46E-01
Recessive AA/AG + GG 34/498 33/491 1.02(0.62-1.67) 9.47E-01 0.91(0.53-1.57) 7.31E-01
rs854560 Additive A > T 41/1014 39/996 1.03(0.66-1.61) 8.84E-01 0.95(0.58-1.56) 8.37E-01
Dominant AA + AT/TT 40/507 38/498 1.04(0.65-1.65) 8.78E-01 0.97(0.58-1.62) 9.12E-01
Recessive AA/AT + TT 1/507 1/498 0.98(0.06-15.75) 9.90E-01 0.40(0.02-7.40) 5.39E-01
Variants are described as minor allele or geno; the contrast allele refers to the minor allele; OR: odds ratio; CI: confidence interval; Punjusted: unadjusted P-value
from t-test; Padjusted: P value adjusted using logistic regression analysis with age, HD and hypertension as covariates. F_Stroke and F_Control represent the
frequency of minor allele or geno in total stroke patients and controls respectively. Significant P values (P <0.05) are in bold and P* < 0.005 (Bonferroni multiple
correction threshold).
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sion with or without adjustment for covariates. A single
site association test between rs662 and rs854560 and
ischemic stroke was conducted using an allele-based
model. Bonferroni correction was undertaken for the 10
SNPs that were adopted into the single site association
analysis.
Linkage disequilibrium analysis and haplotype selection
were performed using Haploview software with parameter
settings for pairwise tagging with D’ >0.95 [33]. The Omni-
bus ANOVA test was conducted using R software [34].
Inverse variance meta-analysis (RevMan 4.0 software)
was used to contextualize our studies with two meta-
analyses, using the data from PMID: 20856122 [35] andPMID: 18511872 [30], which also studied the association
between rs662 and rs854560 loci and ischemic stroke.
Values of P <0.005 were considered to represent the
threshold for statistical significance.Results
Clinical characteristics of total stroke patients and
controls
Table 1 shows demographic characteristics and clinical
vascular variables in the control and total stroke patients.
There were no significant differences in levels of TC, TG
and LDL between the controls and total stroke cases.
However, HDL levels were significantly lower in stroke
Table 3 Association between SNPs with ischemic stroke using the additive, dominant, genotype, and the recessive
models
SNP Model Allele or
geno
F_IS Control T-Statistic Logistic Regression
OR (95% CI) Punadjusted OR (95% CI) Padjusted
rs854571 Additive C > T 200/660 344/982 0.80(0.65-0.99) 4.34E-02 0.84(0.66-1.07) 1.62E-01
Dominant CC + CT/TT 170/330 289/491 0.74(0.56-0.98) 3.79E-02 0.80(0.58-1.10) 1.63E-01
Recessive CC/CT + TT 30/330 55/491 0.79(0.50-1.27) 3.31E-01 0.82(0.49-1.37) 4.45E-01
rs13306698 Additive A > G 62/676 98/988 0.91(0.65-1.29) 6.00E-01 1.07(0.72-1.59) 7.43E-01
Dominant AA + AG/GG 61/338 96/494 0.91(0.64-1.30) 6.16E-01 1.09(0.72-1.64) 6.83E-01
Recessive AA/AG + GG 1/338 2/494 0.73(0.07-8.08) 7.98E-01 0.55(0.04-7.85) 6.63E-01
rs854572 Additive C > G 285/668 413/964 0.99(0.82-1.21) 9.44E-01 0.98(0.78-1.23) 8.29E-01
Dominant CC + CG/GG 220/334 324/482 0.94(0.70-1.27) 6.87E-01 0.94(0.67-1.32) 7.23E-01
Recessive CC/CG + GG 65/334 89/482 1.07(0.75-1.52) 7.21E-01 1.01(0.67-1.53) 9.70E-01
rs7493 Additive C > G 124/676 176/974 1.02(0.79-1.32) 8.85E-01 0.98(0.73-1.31) 8.82E-01
Dominant CC + CG/GG 114/338 163/487 1.01(0.75-1.36) 9.39E-01 0.99(0.71-1.39) 9.68E-01
Recessive CC/CG + GG 10/338 13/487 1.11(0.48-2.57) 8.04E-01 0.85(0.34-2.12) 7.23E-01
rs662 Additive G > A 276/674 356/978 1.19(0.98-1.45) 7.34E-02 1.18(0.94-1.47) 1.46E-01
Dominant GG + GA/AA 212/337 282/489 1.25(0.94-1.66) 1.31E-01 1.20(0.86-1.66) 2.84E-01
Recessive GG/GA + AA 64/337 74/489 1.32(0.91-1.90) 1.45E-01 1.35(0.88-2.06) 1.67E-01
rs12026 Additive C > G 124/672 174/978 1.05(0.81-1.36) 7.26E-01 1.02(0.76-1.37) 8.78E-01
Dominant CC + CG/GG 114/336 162/389 1.04(0.77-1.39) 8.11E-01 1.04(0.74-1.45) 8.33E-01
Recessive CC/CG + GG 10/336 12/489 1.22(0.52-2.86) 6.48E-01 0.95(0.38-2.42) 9.21E-01
rs1053275 Additive A > G 144/666 186/994 1.19(0.94-1.52) 1.51E-01 1.17(0.89-1.54) 2.70E-01
Dominant AA + AG/GG 129/333 165/497 1.27(0.95-1.70) 1.02E-01 1.24(0.89-1.73) 2.10E-01
Recessive AA/AG + GG 15/333 21/497 1.07(0.54-2.11) 8.47E-01 1.07(0.49-2.31) 8.68E-01
rs705381 Additive G > A 74/660 151/990 0.70(0.52-0.95) 2.02E-02 0.65(0.47-0.92) 1.35E-02
Dominant GG + GA/AA 65/330 144/395 0.60(0.43-0.83) 2.50E-03* 0.54(0.37-0.79) 1.67E-03*
Recessive GG/GA + AA 9/330 7/495 1.96(0.72-5.30) 1.88E-01 1.85(0.60-5.64) 2.83E-01
rs2074353 Additive A > G 176/662 230/982 1.18(0.94-1.47) 1.53E-01 1.23(0.95-1.60) 1.09E-01
Dominant AA + AG/GG 153/331 197/491 1.28(0.97-1.70) 8.30E-02 1.38(1.00-1.91) 5.29E-02
Recessive AA/AG + GG 23/331 33/491 1.04(0.60-1.80) 8.99E-01 1.06(0.56-1.99) 8.69E-01
rs854560 Additive A > T 30/674 39/996 1.14(0.70-1.85) 5.93E-01 1.19(0.69-2.07) 5.36E-01
Dominant AA + AT/TT 29/337 38/498 1.14(0.69-1.89) 6.11E-01 1.24(0.70-2.21) 4.57E-01
Recessive AA/AT + TT 1/337 1/498 1.48(0.09-23.73) 7.82E-01 0.43(0.02-9.62) 5.92E-01
Variants are described as minor allele or geno and the contrast allele refers to the minor allele; OR: odds ratio; CI: confidence interval; Punjusted: unadjusted P-value
from t-test; Padjusted: P value adjusted using logistic regression analysis with age, HD and hypertension as covariates F_IS and F_Control represent the frequency of
minor allele in ischemic stroke patients and controls respectively. Significant P values (P < 0.05) are in bold and P* < 0.005 (Bonferroni multiple
correction threshold).
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hypertension were significantly higher.
Linkage disequilibrium
A total of eleven gene polymorphisms were genotyped
in the cases and controls. For PON1 these included three
coding-region polymorphisms (rs662/Q192R, rs13306698/
Arg160Gly, and rs854560/Leu55Met) and four regulatory-
region polymorphisms (rs705379/-107/-108, rs705381/-
160/-162, rs854571/-824/-832, and rs854572/-907/-909).
There were also two coding-region polymorphisms of
PON2 (rs12026/Ala148Gly, and rs7493/Ser311Cys), and
two coding-region polymorphisms of PON3 (rs2074353located in intron and rs1053275/Ala99Ala). The total rate
of successful genotyping was 98.6%. All genotype distribu-
tions within the studied polymorphisms were in Hardy-
Weinberg equilibrium (P >0.05), in both cases and controls,
except for rs705379 (−107/-108) (P <0.001), which was
located in the promoter of PON1.
The results of linkage disequilibrium evaluation ana-
lyses are shown in Figure 1A. In this analysis, SNPs with
a pairwise r2 >0.9 were considered to be in the same
block. Based on this approach, four haplotype blocks
(Block1: rs854560-rs13306698-rs662; Block2: rs854572-
rs854571-rs705381; Block3: rs1053275-rs2074353; Block4:
rs12026-rs7493) were identified (Figure 1B).
Table 4 Association between SNPs and hemorrhagic stroke using the additive, dominant, genotype, and the recessive
models
SNP Model Allele or
geno
F_HS F_Control T-Statistic Logistic Regression
OR (95% CI) Punadjusted OR (95% CI) Padjusted
rs854571 Additive C > T 92/316 344/982 0.76(0.57-1.00) 5.00E-02 0.76(0.57-1.01) 5.54E-02
Dominant CC + CT/TT 78/158 289/491 0.68(0.48-0.98) 3.68E-02 0.70(0.48-1.01) 5.57E-02
Recessive CC/CT + TT 14/158 55/491 0.77(0.42-1.43) 4.08E-01 0.71(0.38-1.34) 2.95E-01
rs13306698 Additive A > G 33/324 98/988 1.03(0.67-1.59) 8.85E-01 1.06(0.68-1.66) 7.93E-01
Dominant AA + AG/GG 33/162 96/494 1.06(0.68-1.65) 7.95E-01 1.09(0.69-1.72) 7.06E-01
Recessive AA/AG + GG 0/162 2/494 0.00(0.00-inf) 9.99E-01 0.00(0.00-inf) 9.99E-01
rs854572 Additive C > G 151/320 413/964 1.20(0.93-1.54) 1.73E-01 1.24(0.95-1.61) 1.20E-01
Dominant CC + CG/GG 118/160 324/482 1.37(0.92-2.04) 1.23E-01 1.38(0.91-2.08) 1.27E-01
Recessive CC/CG + GG 33/160 89/482 1.15(0.73-1.79) 5.46E-01 1.25(0.79-1.99) 3.38E-01
rs7493 Additive C > G 64/324 176/974 1.12(0.81-1.55) 4.94E-01 1.05(0.75-1.46) 7.77E-01
Dominant CC + CG/GG 57/162 163/487 1.08(0.74-1.57) 6.90E-01 1.03(0.70-1.51) 8.94E-01
Recessive CC/CG + GG 7/162 13/487 1.65(0.65-4.20) 2.97E-01 1.28(0.49-3.36) 6.13E-01
rs662 Additive G > A 108/324 356/978 0.88(0.68-1.14) 3.36E-01 0.85(0.65-1.12) 2.48E-01
Dominant GG + GA/AA 88/162 282/489 0.87(0.61-1.25) 4.56E-01 0.82(0.56-1.18) 2.85E-01
Recessive GG/GA + AA 20/162 74/489 0.79(0.47-1.34) 3.83E-01 0.80(0.46-1.38) 4.26E-01
rs12026 Additive C > G 64/322 174/978 1.15(0.83-1.59) 3.95E-01 1.10(0.78-1.53) 5.92E-01
Dominant CC + CG/GG 57/161 162/389 1.11(0.76-1.61) 5.96E-01 1.07(0.72-1.57) 7.44E-01
Recessive CC/CG + GG 7/161 12/489 1.81(0.70-4.67) 2.22E-01 1.47(0.55-3.92) 4.39E-01
rs1053275 Additive A > G 58/318 186/994 0.97(0.71-1.33) 8.55E-01 0.96(0.70-1.33) 8.07E-01
Dominant AA + AG/GG 49/159 165/497 0.90(0.61-1.32) 5.77E-01 0.91(0.61-1.35) 6.36E-01
Recessive AA/AG + GG 9/159 21/497 1.36(0.61-3.03) 4.53E-01 1.17(0.51-2.69) 7.09E-01
rs705381 Additive G > A 32/312 151/990 0.62(0.41-0.94) 2.42E-02 0.62(0.40-0.95) 2.90E-02
Dominant GG + GA/AA 30/156 144/395 0.58(0.37-0.90) 1.61E-02 0.57(0.36-0.90) 1.65E-02
Recessive GG/GA + AA 2/156 7/495 0.91(0.19-4.40) 9.02E-01 1.22(0.24-6.22) 8.13E-01
rs2074353 Additive A > G 74/340 230/982 0.99(0.74-1.32) 9.57E-01 0.96(0.72-1.29) 8.05E-01
Dominant AA + AG/GG 63/159 197/491 0.98(0.68-1.41) 9.11E-01 0.98(0.67-1.42) 8.98E-01
Recessive AA/AG + GG 11/159 33/491 1.03(0.51-2.09) 9.31E-01 0.87(0.42-1.82) 7.21E-01
rs854560 Additive A > T 9/324 39/996 0.70(0.34-1.46) 3.46E-01 0.57(0.26-1.25) 1.58E-01
Dominant AA + AT/TT 9/162 38/498 0.71(0.34-1.51) 3.74E-01 0.57(0.26-1.28) 1.74E-01
Recessive AA/AT + TT 0/162 NA NA NA NA NA
Variants are described as minor allele or geno and the contrast allele refers to the minor allele; Punjusted: unadjusted P-value from t-test; Padjusted: P value adjusted
using logistic regression analysis with age, HD and hypertension as covariates. F_HS and F_Control represent the frequency of minor allele in hemorrhagic stroke
patients and controls respectively. NA means not applicable. Significant P values (P < 0.05) are in bold.
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The association between the ten SNPs included in the four
blocks and total stroke occurrence was analyzed using
additive, dominant, genotype, and recessive models. As
shown in Table 2, two polymorphisms, rs705381 and
rs854571 were significantly associated with total stoke
using additive and dominant models. The allele A of
rs705381 and the allele T of rs854571 were both less fre-
quent in patients with total stroke than in controls. The
association remained significant after logistic regression
analysis adjusting for age, HDL and hypertension using
the additive model (rs705381, Padjusted = 0.0058, OR = 0.67
[95% CI = 0.50-0.89]; and rs854571, Padjusted = 0.0330, OR= 0.80 [95% CI = 0.65-0.98]). However, both P-values failed
to reach significance after the Bonferroni adjustment for
multiple comparisons. Analysis using the dominant
model, showed that the differences in rs705381 remained
significant after Bonferroni correction (Padjusted = 0.0007,
OR = 0.57 [95% CI = 0.41-0.79]), but the differences in
rs854571 did not. There was no significant association be-
tween any of the SNPs of PON genes and total strokes
when analyzed using the recessive model.
As shown in Table 3, rs705381 was significantly
associated with ischemic stroke after adjustment of
confounders in both additive and dominant models
(Padjusted = 0.0017, OR = 0.54 [95% CI = 0.37-0.79]).
Table 5 Haplotypes of the four blocks between total
strokes and control subjects
Haplotype Logistic Regression
OR Punadjusted OR Padjusted
Block1: rs854560-rs13306698-rs662
OMNIBUS NA 0.9371 NA 0.9569
TAA 1.03 0.8820 0.95 0.8390
AAA 1.08 0.4170 1.06 0.5790
AGG 0.95 0.7640 0.98 0.8840
AAG 0.94 0.4810 0.96 0.6580
Block2: rs854572-rs854571-rs705381
OMNIBUS NA 0.0129 NA 0.0394
CTT 1.05 0.6170 1.08 0.4200
CTC 0.64 0.0013 0.65 0.0037
GCC 0.99 0.9110 0.99 0.9280
CCC 1.24 0.0442 1.19 0.1420
Block3: rs1053275-rs2074353
OMNIBUS NA 0.4970 NA 0.5757
GG 1.10 0.3970 1.10 0.4210
AG 1.09 0.6630 1.13 0.5880
AA 0.90 0.2920 0.89 0.3010
Block4: rs12026-rs7493
OMNIBUS NA 0.2479 NA 0.5467
GG 1.08 0.5390 1.03 0.8430
CC 0.92 0.5020 0.96 0.7660
Haplotypes observed in <1% of the control subjects are not listed in the table.
OR: odds ratio; Punjusted: unadjusted P-value from t-test; Padjusted: P value
adjusted using logistic regression analysis with age, HD and hypertension as
covariates. OMIBUS value was calculated by an ANOVA analysis for including
or not including the haplotype information in a likelihood ration test of nested
model. The OR in one block for each haplotype was calculated by using all the
other haplotypes in the same block as the reference haplotype. Significant P
values (P < 0.05) are in bold.
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was found using the recessive model.
Rs854571 was associated with hemorrhagic stroke, with
marginal significance (Punadjusted = 0.0500, OR = 0.76 [95%
CI = 0.57-1.00]) using the additive model, and rs705381
showed a significant association in both additive
(Padjusted = 0.0290, OR = 0.62 [95% CI = 0.40-0.95]) and
dominant models (Padjusted = 0.0165, OR = 0.57 [95%
CI = 0.36-0.90]) (Table 4). However, neither of the two
SNPs was significantly associated with hemorrhagic
stroke after the Bonferroni correction. Thus, there was
no significant finding for hemorrhagic stroke with any
of the three models.
Haplotype analysis
Haplotype analysis conducted in the four blocks, with or
without adjustment for age, HDL and hypertension as cov-
ariates is shown in Table 5. Block 2 consisting of rs854572,
rs854571 and rs705381 was associated with total stroke
(P = 0.0129 Omnibus test), and included one protectivehaplotype C-T-C (OR = 0.64; Punadjusted = 0.0013,)
and one nominal risk haplotype C-C-C (OR = 1.24;
Punadjusted = 0.0442,). The association for haplotype C-
T-C remained significant after adjustment for age, HDL
and hypertension as covariates (OR = 0.65; P = 0.0037).
No other significant haplotype associations were found.
Meta-analysis
Two meta-analyses, PMID: 20856122 [35] and PMID:
18511872 [30], which studied the association between
rs662 and rs854560 loci and ischemic stroke were con-
textualized with our study using the random effects
model. Forests plot for rs662 from 25 studies including
our own are shown in Figure 2. There was a nominal
significant association between rs662 and ischemic stroke
(P = 0.0100, OR = 1.08 [95% CI = 1.02-1.15]) yielding 1.08
per G allele copy, with no statistical evidence for statistical
heterogeneity (P = 0.0400, I2 = 36%) between studies.
There was no evidence of an association between
rs854560 and ischemic stroke risk (P = 0.3700, OR = 0.97
[95% CI = 0.91-1.04]) and no evidence of heterogeneity
(P = 0.2700, I2 = 16%) between studies (Figure 3).
Discussion
The present study investigated the association of 11
polymorphisms in 3 PON genes with the risk of stroke.
Using a dominant model, we demonstrated that rs705381
(−162) was significantly associated with total stroke and
ischemic stroke but not with hemorrhagic stroke. There
was also a nominal association between rs854571 (−824)
and stroke with the allele T as a protective factor.
Both rs705381 and rs854571 polymorphisms located in
the promoter region of PON1 were associated with stroke,
which was consistent with previous findings [19,36-39].
The protective effect of -162 T polymorphism on total
stroke and ischemic stroke was also consistent with previ-
ous observations [40] which suggested that NF-1, a ubi-
quitous nuclear factor and a transcriptional activator, has
a binding site on PON1 if allele A appears at −162. Other
studies have shown that -162 T polymorphism results in
higher expression levels of PON1 [40,41] There is also evi-
dence to suggest a correlation between AA (−162) and
high PON activities in Caucasians [42].
Our results support the hypothesis that the protective
effect of -162 T polymorphism might be attributable to
high PON activity [42]. We also found weak evidence to
suggest that -824 T was associated with a reduced propen-
sity to suffer stroke. However, the evidence was no longer
apparent after Bonferroni correction for multiple compar-
isons. It has been previously reported that -824 T (824A
in their finding) was associated with low serum PON
levels [43]. Negative associations between −162 and −824
have been reported in studies in American populations
[23,40]. These findings highlight the potential influence of
Figure 2 Meta-analysis of studies investigating the association of PON1 rs662 with ischemic stroke using a random effects model. The
point estimate of the OR (square proportional to the weight of each study) and 95% CI for the OR (extending lines) for each study. The summary
OR and 95% CIs by random effects calculations are depicted as a diamond. Values higher than 1 indicate that the G allele is associated with
increased risk of ischemic stroke.
Figure 3 Meta-analysis of studies investigating the association of PON1 rs854560 with ischemic stroke using a random effects model.
Values higher than 1 indicate that the A allele is associated with increased risk of ischemic stroke risk. The layout is the same as that in Figure 2.
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identical-by-descent principles [44,45].
Patients with coronary heart disease (CHD) have been
shown to have a higher frequency of -162 T allele than
the controls, suggesting allele A may be associated with
risk of CHD in the Han Chinese population [46]. How-
ever, in our study, we found a protective effect of the
-162 T polymorphism on stroke.
Haplotype analysis further confirmed our positive
results and identified a positive association between the
protective haplotype C-T-C and the risk haplotype C-C-C
of rs854572-rs854571-rs705381 (Block 2) with total stroke.
No significant associations were observed for stroke sus-
ceptibility with the two coding region polymorphisms in
PON2, which was consistent with previous findings in the
Han Chinese population and in North Americans [24,29],
although a positive association of Ser311Cys was found in
a Polish population [22].
The absence of any positive correlations between stroke
risk and the two PON3 polymorphisms in our study was
also consistent with reported findings in Caucasian and
North American patients [24,27].
Our study was conducted in a relatively large Chinese
sample pool and included careful assessment of two
stroke subtypes. We also selected common variants in
all three members of the PON gene family. However,
functional detection of PON activities was not under-
taken in the present study and investigation of the asso-
ciation between SNPs and large or small vessel strokes
was not possible as a complete classification of the sub-
type of ischemic stroke subjects was not available in our
study. In our study, results from both adjusted and un-
adjusted analyses were in line with each other. However,
in other settings, authorities have discouraged the use of
data adjustments for the determination of the total gen-
etic effect [47]. It, therefore, remains uncertain as to
whether adjusted or unadjusted data should be used to
interpret our results in clinical context.
Conclusion
The study identified rs705381 (−162) as being significantly
associated with total stroke and ischemic stroke, and
demonstrated a weak association for rs854571 (−824) in
the Han Chinese population. These findings support the
involvement of PON polymorphisms in the development
of stroke. Further studies with larger sample sizes are
required to validate these findings and to elucidate the
underlying biological mechanisms.
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